查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990479

造影超音波市場：依方法、技術、應用和最終用戶分類－2026-2032年全球市場預測

Contrast Enhanced Ultrasound Market by Mode, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，造影超音波市場價值將達到 23.5 億美元，到 2026 年將成長至 24.9 億美元，到 2032 年將達到 36.9 億美元，複合年成長率為 6.64%。

主要市場統計數據
基準年 2025 23.5億美元
預計年份：2026年 24.9億美元
預測年份 2032 36.9億美元
複合年成長率 (%) 6.64%

簡潔而有策略地將對比造影超音波為一種具有臨床影響力的診斷方法，它重塑了患者的治療路徑和影像診斷方面的決策。

造影超音波結合了微氣泡造影造影和先進的超音波技術，是診斷影像領域的重大進步，它能夠顯著改善病灶顯像、血管評估和即時功能評估。在過去十年間，臨床醫生擴大利用造影超音波來提高肝病學、腫瘤學、循環系統和急診醫學的診斷準確性，同時，診斷影像團隊也在尋求能夠減少輻射暴露並提高患者診療效率的影像方式。本文認為，造影超音波不僅是一項技術革新，更是一種實用的臨床工具，它正在重塑急診和門診等各種診療場景下的診斷流程。

這是一個重要的技術、臨床和商業性轉折點，正在加速醫療保健領域的採用，並重塑實施方法。

在造影超音波領域，正在發生多項變革性變化，這些變化正在重新調整臨床實踐、採購和創新的優先事項。換能器設計、訊號處理和造影配方方面的進步正在提高超音波在血管表徵和病變評估中的靈敏度和特異性。同時，軟體分析和人工智慧影像增強技術的整合，正使影像診斷從完全依賴操作者轉向更標準化的評估，從而支持不同醫療機構和臨床醫生之間診斷結果的可重複性。

關稅政策的變化對造影超音波技術的供應鏈、採購決策和臨床應用趨勢產生了哪些影響？

近期貿易政策推出導致的新關稅措施已成為採購負責人、製造企業負責人和臨床營運團隊必須重點考慮的問題。影響進口零件、成品超音波診斷設備和藥用級造影劑的關稅可能會造成下游成本壓力，進而導致資本投資放緩和籌資策略的重新評估。醫療系統和影像中心目前不僅要評估各項成本，還要評估總體擁有成本 (TCO)，其中包括在貿易環境變化下的維護、培訓和供應連續性等成本。

詳細的細分分析揭示了模式選擇、技術方法、臨床適應症和最終用戶特徵如何影響採用管道和採購選擇。

細分洞察揭示了成像模式選擇、成像技術、臨床應用和最終用戶畫像如何相互交織，共同決定部署模式和投資優先順序。成像模式的選擇會影響工作流程。例如，多普勒成像可輔助血管評估和血流定量，諧波成像可提高病灶檢測中組織對比度的分離度，而即時成像則支援床邊操作過程中的連續可視化。每種成像模式都有其獨特的學習曲線和通訊協定要求，相關人員必須使其與臨床目標和人員配置模式相協調。

區域採用趨勢、全球臨床實施、與報銷制度的一致性以及決定供應鏈韌性的區域特定策略考量。

區域趨勢受獨特的採納因素、監管考慮和營運重點的影響，這些因素共同作用，影響著造影超音波的普及應用。在美洲，醫保報銷機制、大規模綜合醫療保健系統以及對床邊影像的高度重視，持續推動急診和循環系統的臨床應用。對培訓計畫的投入以及集中式研究網路的存在，有助於在區域層面產生循證醫學證據，並支持更廣泛的臨床應用以及整個醫療保健網路內的通訊協定標準化。

主要企業正致力於整合硬體、造影劑最佳化、高階軟體分析和服務主導模式，以確保臨床部署的成功。

造影超音波領域的公司正著力於幾個相互融合的優先事項，以保持其臨床意義和商業性發展勢頭。產品研發的投資主要集中在改進用戶工程設計、提升探頭技術以提高穿透力和解析度，以及整合先進的軟體工具以實現造影劑定量和灌注成像的自動化。這些改進旨在減少操作者差異，並創建可重複的指標，以便將其納入臨床決策演算法。

制定可操作的策略重點，協調臨床證據的產生、產品可用性和供應鏈韌性，以加速在所有醫療保健環境中的永續部署。

產業領導者應推動一系列合作舉措，將臨床證據、商業化和供應鏈韌性相結合，以加速造影超音波的持續應用。應優先投資於多中心臨床研究，以產生可靠的療效比較證據，證明造影超音波技術與有意義的臨床終點和運作效率之間的關聯。加強證據基礎將有助於與保險公司和臨床管治委員會進行建設性對話，並促進該技術在不斷變化的報銷限制下獲得更廣泛的認可。

採用嚴謹的混合方法研究途徑，結合對臨床醫師的訪談、監管審查、技術檢驗和證據三角檢驗，以確保研究結果的可靠性。

本分析的調查方法結合了嚴謹的定性和定量方法，以確保研究結果具有實證基礎，並與臨床實踐密切相關。關鍵的定性資料包括對循環系統、放射學、腫瘤學和急診醫學領域的臨床醫生、醫院和影像中心的採購經理以及系統整合商和造影劑生產商的技術專家進行的結構化訪談。這些訪談深入剖析了影響採納決策的實際工作流程、訓練需求和採購考量。

對增強造影的臨床價值提案、操作前提條件和廣泛應用面臨的策略挑戰進行綜合分析。

造影超音波正處於一個重要的轉折點，臨床效用、技術成熟度和實際操作條件在此交匯融合，為改善診斷醫學創造了切實的機會。該技術的優勢——即時灌注成像、良好的安全性以及床邊應用性——使其成為循環系統、腫瘤學、急診醫學以及更廣泛的診斷流程中的輔助工具。然而，要充分發揮其潛力，需要在實證醫學、教育和商業策略方面做出協調一致的努力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按模式造影超音波市場

  • 多普勒影像
  • 諧波成像
  • 即時成像

第9章造影超音波市場：依技術分類

  • 高機械指數成像
  • 低機械指數成像

第10章造影超音波市場：依應用領域分類

  • 循環系統
  • 緊急醫療護理
  • 腫瘤學
  • 放射科

第11章：造影超音波市場：依最終用戶分類

  • 學術和研究機構
  • 門診手術中心
  • 診斷影像中心
  • 醫院

第12章：造影超音波市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：造影超音波市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：造影超音波市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國造影超音波市場

第16章 中國造影超音波市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bracco SpA
  • Bristol-Myers Squibb Company
  • Canon Inc.
  • Carestream Health, Inc.
  • Daiichi Sankyo Company, Limited
  • Esaote SpA,
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • Leriva SA
  • Mayo Clinic
  • Medtronics PLC
  • Mobisante, Inc.
  • nanoPET Pharma GmbH
  • Samsung Medison Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • TeraRecon, Inc.
  • Toshiba Corporation
  • Trivitron Healthcare Private Limited
Product Code: MRR-3A68B8397AEE

The Contrast Enhanced Ultrasound Market was valued at USD 2.35 billion in 2025 and is projected to grow to USD 2.49 billion in 2026, with a CAGR of 6.64%, reaching USD 3.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.35 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 3.69 billion
CAGR (%) 6.64%

A concise strategic framing of contrast enhanced ultrasound as a clinically impactful diagnostic modality reshaping patient pathways and imaging decision making

Contrast enhanced ultrasound represents a pivotal evolution in diagnostic imaging, combining microbubble contrast agents with advanced ultrasound modalities to enhance lesion conspicuity, vascular assessment, and real-time functional evaluation. Over the last decade, clinicians have increasingly leveraged contrast enhanced ultrasound to refine diagnostics in hepatology, oncology, cardiology, and emergency medicine, while imaging teams pursue modalities that reduce radiation exposure and streamline patient throughput. This introduction frames contrast enhanced ultrasound not merely as an incremental technology but as a practical clinical tool reshaping diagnostic pathways across acute and ambulatory settings.

The clinical appeal of contrast enhanced ultrasound stems from its safety profile, repeatability at the bedside, and the capacity to deliver dynamic perfusion information without ionizing radiation. Practitioners benefit from portable deployment and the immediacy of real-time imaging, enabling faster diagnostic decisions in emergency departments and procedural guidance in interventional suites. Concurrently, imaging departments and health systems have sought to integrate contrast protocols into standard workflows, balancing training needs with procedural efficiencies and reimbursement considerations.

As a strategic framing, this introduction emphasizes the interplay between clinical evidence generation, technology maturation, and stakeholder adoption. It sets the stage for deeper analysis of technological shifts, regulatory landscapes, procurement dynamics, and the commercial actions necessary to translate clinical potential into sustainable clinical practice.

Critical technological, clinical, and commercial inflection points that are driving widespread adoption and reshaping implementation approaches across care settings

The landscape for contrast enhanced ultrasound is undergoing several transformative shifts that recalibrate clinical practice, procurement, and innovation priorities. Advances in transducer design, signal processing, and contrast agent formulations are augmenting the sensitivity and specificity of ultrasound for vascular characterization and lesion assessment. Simultaneously, the integration of software analytics and AI-enabled image enhancement is transitioning interpretation from purely operator dependent to more standardized assessments, supporting reproducibility across institutions and clinicians.

Clinical protocols are evolving in parallel: cross-disciplinary guidelines increasingly recognize the role of contrast enhanced ultrasound in targeted applications, which fosters collaborative pathways between radiology, cardiology, oncology, and emergency medicine. This multidisciplinary adoption is encouraging clinical trials that expand indications and strengthen evidence for noninvasive diagnostic strategies. Additionally, point-of-care adoption is rising as emergency and critical care clinicians employ contrast techniques to expedite triage and therapeutic decisions, thereby reducing time to intervention in acute scenarios.

From a commercial standpoint, the market is witnessing consolidation of hardware and contrast agent strategies, with vendors focusing on platform differentiation through ease of use, automated workflows, and regulatory clarity. Supply chain resilience and strategic partnerships between imaging system manufacturers and contrast agent suppliers are becoming critical to ensure consistent clinical availability. These converging shifts underscore a rebalancing from technology novelty toward practical clinical integration and scalable adoption.

How evolving tariff policies are reshaping supply chains, procurement decisions, and clinical adoption dynamics for contrast enhanced ultrasound technologies

The imposition of new tariff measures originating from recent trade policy decisions has introduced a material consideration for procurement planners, manufacturing leaders, and clinical operations teams. Tariffs affecting imported components, finished ultrasound systems, and pharmaceutical-grade contrast agents create downstream cost pressures that can slow capital purchases and prompt reevaluation of sourcing strategies. Health systems and imaging centers are now assessing not only unit costs but also total cost of ownership, which includes maintenance, training, and supply continuity under altered trade conditions.

Operationally, providers are responding by diversifying supplier relationships, increasing inventory buffers for critical consumables, and exploring local assembly or regional distribution partnerships to mitigate tariff exposure. Some manufacturers are accelerating qualification of alternative suppliers and exploring relocation of key manufacturing steps to tariff-advantaged jurisdictions to preserve competitive pricing for end users. These shifts also influence clinical adoption timelines, as procurement committees may delay upgrades pending clearer tariff trajectories or seek financing arrangements to spread capital impact over multiple fiscal periods.

Clinically, the potential for higher per-procedure costs necessitates evidence that contrast enhanced ultrasound delivers measurable improvements in diagnostic accuracy, clinical throughput, or patient outcomes that offset incremental expense. Accordingly, groups responsible for clinical governance are intensifying comparative effectiveness studies and health economics analyses to justify continued adoption under the revised cost environment. The cumulative impact of tariff dynamics is therefore multi-dimensional, affecting supply chain architecture, capital planning, and the evidentiary case for procedure-level adoption.

Deep segmentation intelligence revealing how mode selection, technological approaches, clinical indications, and end user characteristics shape adoption pathways and procurement choices

Insight into segmentation reveals how modality choices, imaging technology, clinical applications, and end-user profiles collectively dictate adoption patterns and investment priorities. Mode selection influences operational workflows; for example, Doppler imaging techniques complement vascular assessments and flow quantification, while harmonic imaging enhances contrast-to-tissue separation for focal lesion detection, and real-time imaging supports continuous visualization during bedside procedures. Each mode presents distinct training curves and protocol requirements that stakeholders must reconcile with clinical objectives and staffing models.

Technology differentiation further shapes clinical utility and workflow efficiency. High mechanical index imaging enables targeted microbubble destruction and reperfusion assessment that can be advantageous for specific perfusion studies, whereas low mechanical index imaging supports continuous real-time contrast visualization without signal disruption, making it well suited for dynamic assessments in interventional settings. These technological choices affect equipment selection and protocol development, and they often drive vendor conversations around compatibility and software capabilities.

Application-driven priorities create clear use cases that appeal to different clinical stakeholders. Cardiology leverages contrast for enhanced endocardial border definition and myocardial perfusion assessment, while emergency medicine values rapid bedside diagnostic confirmation and trauma evaluation. Oncology benefits from tumor perfusion characterization to guide biopsy and monitor therapy response, and radiology integrates contrast enhanced ultrasound as a radiation-free adjunct for lesion characterization. End users vary in operational scale and clinical complexity; academic and research institutes emphasize protocol innovation and evidence generation, ambulatory surgical centers prioritize throughput and cost efficiency, diagnostic imaging centers focus on specialized workflows and outpatient access, and hospitals require integration across inpatient and outpatient services. Taken together, these segmentation perspectives inform product positioning, clinical engagement strategies, and training investments to maximize clinical relevance and operational feasibility.

Regional adoption dynamics and localized strategic considerations that determine clinical uptake, reimbursement alignment, and supply chain resilience across global territories

Regional dynamics present distinct adoption drivers, regulatory considerations, and operational priorities that influence the diffusion of contrast enhanced ultrasound. In the Americas, reimbursement structures, large integrated health systems, and a strong emphasis on point-of-care imaging continue to drive clinical uptake in emergency departments and cardiology services. Investment in training programs and the presence of centralized research networks foster local evidence generation, supporting broader clinical acceptance and protocol standardization across health networks.

Europe, Middle East & Africa comprise a heterogeneous landscape in which regulatory frameworks, public health priorities, and infrastructure variability result in differentiated adoption rates. Several European healthcare systems demonstrate robust integration of contrast enhanced ultrasound within hepatology and oncology pathways, while regions with constrained resources prioritize cost-effective modalities and streamlined training to expand diagnostic capacity. Cross-border collaborations and pan-regional clinical guidelines play a significant role in harmonizing practice and accelerating evidence dissemination across national boundaries.

The Asia-Pacific region is characterized by rapid capital investment in imaging infrastructure, strong private provider networks, and substantial growth in procedural volumes. Clinical demand is being driven by expanding oncology services and an increasing focus on minimally invasive diagnostics. Local manufacturing capabilities and regional supply chains also influence procurement strategies, making partnerships with regional distributors and localized service models particularly important for sustained adoption. Collectively, these regional insights highlight the need for tailored commercial approaches that align clinical evidence, reimbursement realities, and operational capabilities with local priorities.

How leading companies are converging on integrated hardware, contrast agent alignment, advanced software analytics, and service-driven models to secure clinical adoption

Companies operating in the contrast enhanced ultrasound space are focusing on several convergent priorities to sustain clinical relevance and commercial momentum. Product development investments center on enhancing user ergonomics, improving probe technology for better penetration and resolution, and integrating advanced software tools that automate contrast quantification and perfusion mapping. These capabilities aim to reduce operator variability and create reproducible metrics that can be incorporated into clinical decision algorithms.

Strategic partnerships between imaging system vendors and contrast agent developers are becoming increasingly important to ensure end-to-end compatibility and to streamline regulatory pathways. Firms are also augmenting their offerings with service models that include training curricula, accreditation support, and outcome-tracking tools to demonstrate clinical value to payers and health system purchasers. On the operational front, companies are optimizing supply chains by regionalizing distribution, qualifying multiple manufacturing partners, and offering flexible procurement arrangements such as subscription and pay-per-use models to lower the barrier to entry for cost-sensitive buyers.

Competitive differentiation is shifting from hardware features alone toward integrated solutions that combine imaging hardware, contrast agent consumables, software analytics, and clinical education. This integrated approach supports adoption by addressing clinical, operational, and financial decision criteria simultaneously, and positions companies to better respond to changing regulatory and tariff environments that affect global supply chains.

Actionable strategic priorities that align clinical evidence generation, product usability, and supply chain resilience to accelerate durable adoption across care settings

Industry leaders should pursue a coordinated set of actions that align clinical evidence, commercialization, and supply chain resilience to accelerate sustainable adoption of contrast enhanced ultrasound. Prioritize investment in multicenter clinical collaborations that generate robust comparative effectiveness evidence linking contrast enhanced ultrasound procedures to meaningful clinical endpoints and operational efficiencies. Strengthening the evidentiary base will support constructive engagements with payers and clinical governance committees, enabling broader procedural acceptance under evolving reimbursement constraints.

Simultaneously, accelerate integration of user-centric software and automated workflows that reduce operator dependency and lower training barriers. Embedding quantitative perfusion analytics and decision support directly into imaging platforms will improve reproducibility and create data assets that demonstrate value across care pathways. From a commercial and operational perspective, diversify supplier networks, regionalize critical component manufacturing, and develop flexible procurement offerings that reduce exposure to tariff volatility and capital constraints.

Finally, invest in scaled clinical education programs and credentialing pathways that equip a broader cohort of clinicians to perform contrast enhanced ultrasound safely and effectively. Partnerships with academic institutions and specialty societies can amplify adoption through guideline alignment and continuing education. By combining evidence generation, product usability enhancements, supply chain strategies, and education initiatives, industry leaders can create defensible adoption pathways that withstand policy shifts and competitive pressures.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, technical validation, and evidence triangulation to ensure robust insights

The research methodology underpinning this analysis combined rigorous qualitative and quantitative approaches to ensure findings are evidence-based and practitioner-relevant. Primary qualitative inputs included structured interviews with clinicians across cardiology, radiology, oncology, and emergency medicine, procurement leaders in hospitals and imaging centers, and technical experts from system integrators and contrast agent manufacturers. These interviews provided rich insights into real-world workflows, training needs, and procurement considerations that shape deployment decisions.

Secondary research entailed systematic review of peer-reviewed clinical studies, regulatory guidance documents, professional society position statements, and technology white papers to triangulate clinical performance claims and safety profiles. Technical assessments of device capabilities and imaging modalities were corroborated with vendor product literature and independent bench testing reports. Data synthesis used a triangulation approach that reconciled clinician perspectives, regulatory context, and technical specifications to derive actionable insights while maintaining transparency about evidence sources and any limitations.

Quality assurance steps included cross-validation of interview findings with clinical trial outcomes, sensitivity checks for supply chain and tariff assumptions, and peer review by subject matter experts. Ethical considerations and patient safety factors were integrated throughout the methodology, ensuring that recommendations prioritize clinical benefit and operational viability.

Consolidated conclusions on the clinical value proposition, operational prerequisites, and strategic imperatives for broader adoption of contrast enhanced ultrasound

Contrast enhanced ultrasound stands at a pragmatic inflection point where clinical utility, technological maturity, and operational realities converge to create tangible opportunities for improved diagnostic care. The modality's strengths-real-time perfusion imaging, favorable safety profile, and bedside applicability-position it as a complementary tool across cardiology, oncology, emergency medicine, and broader diagnostic workflows. However, realizing its full potential requires aligned efforts across evidence generation, education, and commercial strategy.

Operationally, stakeholders must navigate policy shifts and supply chain complexities that influence procurement timelines and capital investment decisions. Clinical teams and manufacturers that collaborate on standardized protocols, reproducible quantitative measures, and accessible training pathways will be best positioned to accelerate adoption. Companies that integrate hardware, consumables, and analytics into cohesive solutions and that mitigate supply chain risk will create stronger value propositions for health systems and outpatient providers.

In conclusion, contrast enhanced ultrasound offers a clinically meaningful, low-risk imaging option that can improve diagnostic confidence and patient management when deployed with thoughtful evidence, training, and procurement strategies. The path forward is collaborative and requires sustained commitment to demonstrating clinical impact and operational feasibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contrast Enhanced Ultrasound Market, by Mode

  • 8.1. Doppler Imaging
  • 8.2. Harmonic Imaging
  • 8.3. Real Time Imaging

9. Contrast Enhanced Ultrasound Market, by Technology

  • 9.1. High Mechanical Index Imaging
  • 9.2. Low Mechanical Index Imaging

10. Contrast Enhanced Ultrasound Market, by Application

  • 10.1. Cardiology
  • 10.2. Emergency Medicine
  • 10.3. Oncology
  • 10.4. Radiology

11. Contrast Enhanced Ultrasound Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Contrast Enhanced Ultrasound Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Contrast Enhanced Ultrasound Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Contrast Enhanced Ultrasound Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Contrast Enhanced Ultrasound Market

16. China Contrast Enhanced Ultrasound Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bracco S.p.A.
  • 17.6. Bristol-Myers Squibb Company
  • 17.7. Canon Inc.
  • 17.8. Carestream Health, Inc.
  • 17.9. Daiichi Sankyo Company, Limited
  • 17.10. Esaote S.p.A,
  • 17.11. FUJIFILM Corporation
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. Hitachi, Ltd.
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Lantheus Holdings, Inc.
  • 17.16. Leriva SA
  • 17.17. Mayo Clinic
  • 17.18. Medtronics PLC
  • 17.19. Mobisante, Inc.
  • 17.20. nanoPET Pharma GmbH
  • 17.21. Samsung Medison Co., Ltd.
  • 17.22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 17.23. Siemens AG
  • 17.24. TeraRecon, Inc.
  • 17.25. Toshiba Corporation
  • 17.26. Trivitron Healthcare Private Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)